Role of folinic acid in methotrexate-based prophylaxis of graft-versus-host disease following hematopoietic stem cell transplantation

References

• Thomas ED, Lochte HL, Lu WC, et al. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med. 1957;257(11):491–496.
   PubMed Web of Science ®Google Scholar
• Henig I, Zuckerman T. Hematopoietic stem cell transplantation-50 years of evolution and future perspectives. Rambam Maimonides Med J. 2014;5(4):e0028.
   PubMedGoogle Scholar
• Thomas ED, Buckner CD, Rudolph RH, et al. Allogeneic marrow grafting for hematologic malignancy using HL-A matched donor-recipient sibling pairs. Blood. 1971;38(3):267–287.
   PubMed Web of Science ®Google Scholar
• Howard SC, McCormick J, Pui CH, et al. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016;21(12):1471–1482.
   PubMed Web of Science ®Google Scholar
• Rampon G, Henkin C, Jorge VM, et al. Methotrexate-induced mucositis with extra-mucosal involvement after acidental overdose. An Bras Dermatol. 2018;93(1):155–156.
   PubMed Web of Science ®Google Scholar
• Gratwohl AA, Bull MI, Graw RG, et al. Methotrexate and citrovorum factor after histoincompatible allogeneic bone marrow transplants in dogs. Acta Haematol. 1978;60(4):233–242.
   PubMed Web of Science ®Google Scholar
• Thomas ED, Storb R, Clift RA, et al. Bone-marrow transplantation (first of two parts). N Engl J Med. 1975;292(16):832–843.
   PubMed Web of Science ®Google Scholar
• Ram R, Storb R. Pharmacologic prophylaxis regimens for acute graft-versus-host disease: past, present and future. Leuk Lymphoma. 2013;54(8):1591–1601.
   PubMed Web of Science ®Google Scholar
• Torres A, Martinez F, Gomez P, et al. Cyclosporin A versus methotrexate, followed by rescue with folinic acid as prophylaxis of acute graft-versus-host disease after bone marrow transplantation. Blut. 1989;58(2):63–68.
   PubMedGoogle Scholar
• Ruutu T, Niederwieser D, Gratwohl A, et al. A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and marrow, transplantation (EBMT). chronic leukaemia working party of the EBMT. Bone Marrow Transplant. 1997;19(8):759–764.
   PubMed Web of Science ®Google Scholar
• Sonis ST, Oster G, Fuchs H, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol. 2001;19(8):2201–2205.
   PubMed Web of Science ®Google Scholar
• Goldman ID, Matherly LH. Biochemical factors in the selectivity of leucovorin rescue: selective inhibition of leucovorin reactivation of dihydrofolate reductase and leucovorin utilization in purine and pyrimidine biosynthesis by methotrexate and dihydrofolate polyglutamates. NCI Monogr. 1987;5(5):17–26.
   Google Scholar
• Bhurani D, Schifter M, Kerridge I. Folinic acid administration following MTX as prophylaxis for GVHD in allogeneic HSCT centres in Australia and New Zealand. Bone Marrow Transplant. 2008;42(8):547–550.
   PubMed Web of Science ®Google Scholar
• Freyer CW, Ganetsky A, Timlin C, et al. Leucovorin following methotrexate graft-vs-host disease prophylaxis shortens the duration of mucositis, time to neutrophil engraftment and length of hospitalization in myeloablative allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant. 2019;25(3):S283.
   Web of Science ®Google Scholar
• Murphy NM, Diviney M, Szer J, et al. The effect of folinic acid on methylenetetrahydrofolate reductase polymorphisms in methotrexate-treated allogeneic hematopoietic stem cell transplants. Biol Blood Marrow Transplant. 2012;18(5):722–730.
   PubMed Web of Science ®Google Scholar
• Peters C, Minkov M, Gadner H, et al. Statement of current majority practices in graft-versus-host disease prophylaxis and treatment in children. Bone Marrow Transplant. 2000;26(4):405–411.
   PubMed Web of Science ®Google Scholar
• Cutler C, Li S, Kim HT, et al. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant. 2005;11(5):383–388.
   PubMed Web of Science ®Google Scholar
• Chaudhry HM, Bruce AJ, Wolf RC, et al. The incidence and severity of oral mucositis among allogeneic hematopoietic stem cell transplantation patients: a systematic review. Biol Blood Marrow Transplant. 2016;22(4):605–616.
   PubMed Web of Science ®Google Scholar
• Nassar A, Elgohary G, Elhassan T, et al. Methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. J Transplant. 2014;2014:1–10.
   Google Scholar
• Genestier L, Paillot R, Fournel S, et al. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest. 1998;102(2):322–328.
   PubMed Web of Science ®Google Scholar
• Bolwell B, Sobecks R, Pohlman B, et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant. 2004;34(7):621–625.
   PubMed Web of Science ®Google Scholar
• Shouval R, Kouniavski E, Fein J, et al. Risk factors and implications of oral mucositis in recipients of allogeneic hematopoietic stem cell transplantation. Eur J Haematol. 2019;103(4):402–409.
   PubMed Web of Science ®Google Scholar
• Sugita J, Matsushita T, Kashiwazaki H, et al. Efficacy of folinic acid in preventing oral mucositis in allogeneic hematopoietic stem cell transplant patients receiving MTX as prophylaxis for GVHD. Bone Marrow Transplant. 2012;47(2):258–264.
   PubMed Web of Science ®Google Scholar
• Freyer CW, Ganetsky A, Timlin C, et al. Leucovorin following methotrexate graft-vs-host disease prophylaxis in myeloablative allogeneic hematopoietic transplantation shortens the duration of mucositis and hospitalization. Blood. 2018;312:5696.
   Google Scholar
• Yeshurun M, Rozovski U, Pasvolsky O, et al. The effect of folinic acid (FA) rescue following MTX gvhd prophylaxis on regimen related toxicity and transplantation outcome: A double blind randomized controlled study. Biol Blood Marrow Transplant. 2020;26(3):S46–S47.
   Web of Science ®Google Scholar
• Kodama Y, Fukano R, Noguchi M, et al. Folinic acid after MTX as prophylaxis for GVHD in pediatric bone marrow transplantation. Int J Hematol. 2015;101(1):92–98.
   PubMed Web of Science ®Google Scholar
• Hudspeth MP, Heath TS, Chiuzan C, et al. Folinic acid administration after MTX GVHD prophylaxis in pediatric allo-SCT. Bone Marrow Transplant. 2013;48(1):46–49.
   PubMed Web of Science ®Google Scholar
• Nevill TJ, Tirgan MH, Deeg HJ, et al. Influence of post-methotrexate folinic acid rescue on regimen-related toxicity and graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1992;9(5):349–354.
   PubMed Web of Science ®Google Scholar
• Lindqvist H, Remberger M, Harila-Saari A, et al. Folinic acid supplementation in higher doses is associated with graft rejection in pediatric hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19(2):325–328.
   PubMedGoogle Scholar
• Russell JA, Woodman RC, Poon MC, et al. Addition of low-dose folinic acid to a methotrexate/cyclosporin A regimen for prevention of acute graft-versus-host disease. Bone Marrow Transplant. 1994;14(3):397–401.
   PubMed Web of Science ®Google Scholar
• Nederlof I, Lindemans CA, Bierings MB, et al. Recognizing a non-classical telomeropathy before hematopoietic stem cell transplantation in pediatric patients: a case series. Hemasphere. 2019;3(4):e282.
   PubMed Web of Science ®Google Scholar